Fate Therapeutics Inc. (FATE)
$2.39
$-0.04
(-1.65%)
As on 31-Aug-2026 16:06EDT
Market cap
$291 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
--
P/B Ratio
2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.1
-
Face value
--
-
Shares outstanding
119,820,514
10 Years Aggregate
CFO
$-811.94 Mln
EBITDA
$-1,082.69 Mln
Net Profit
$-1,089.18 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fate Therapeutics (FATE)
| 143.2 | -4.8 | -15.8 | 129.8 | -3.3 | -49.4 | -1.1 |
|
BSE Sensex*
| -8.9 | -1.2 | 3.2 | -3.3 | 6.0 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Fate Therapeutics (FATE)
| -40.4 | -55.6 | -62.9 | -82.8 | -35.7 | 364.6 | 52.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Fate Therapeutics (FATE)
|
2.4 | 291.2 | 6.5 | -126.0 | -1,476.5 | -69.9 | -- | 2.0 |
| 82.4 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 263.0 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.6 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 106.5 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 359.4 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 540.0 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 594.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 350.3 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Fate Therapeutics (FATE)
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and... T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California. Read more
-
Founder, CEO, President & Director
Mr. J. Scott Wolchko
-
Founder, CEO, President & Director
Mr. J. Scott Wolchko
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Fate Therapeutics (FATE)
What is the current share price of Fate Therapeutics Inc (FATE) Today?
The share price of Fate Therapeutics Inc (FATE) is $2.39 (NASDAQ) as of 31-Aug-2026 16:06 EDT. Fate Therapeutics Inc (FATE) has given a return of -3.26% in the last 3 years.
What is the current PB & PE ratio of Fate Therapeutics Inc (FATE)?
Since, TTM earnings of Fate Therapeutics Inc (FATE) is negative, P/E ratio is not available.
The P/B ratio of Fate Therapeutics Inc (FATE) is 1.98 times as on 28-Aug-2026, a 62 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.86 |
0.56 |
2024 |
-1.04 |
0.61 |
2023 |
-2.29 |
1.00 |
2022 |
-3.85 |
2.03 |
2021 |
-26.42 |
8.26 |
What is the 52 Week High and Low of Fate Therapeutics Inc (FATE)?
The 52-week high and low of Fate Therapeutics Inc (FATE) are Rs 3.23 and Rs 0.93 as of 01-Sep-2026.
What is the market cap of Fate Therapeutics Inc (FATE)?
Fate Therapeutics Inc (FATE) has a market capitalisation of $ 291 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Fate Therapeutics Inc (FATE)?
Before investing in Fate Therapeutics Inc (FATE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.